We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-4.28%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$3.25B
AUM Growth
+$280M
(+9.4%)
Cap. Flow
+$431M
Cap. Flow
% of AUM
13.28%
Top 10 Holdings %
Top 10 Hldgs %
47.18%
Holding
44
New
10
Increased
12
Reduced
9
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$110M |
| 2 |
Universal Health Services
UHS
|
+$102M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$90.7M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$38.5M |
| 5 |
Sanofi
SNY
|
+$38.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cardinal Health
CAH
|
+$71.4M |
| 2 |
SkinHealth Systems
SKIN
|
+$67.2M |
| 3 |
Alkermes
ALKS
|
+$44.5M |
| 4 |
HOLX
Hologic
HOLX
|
+$44.4M |
| 5 |
TBIO
Translate Bio, Inc. Common Stock
TBIO
|
+$38.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.7% |
| 2 | Technology | 2.58% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Teva Pharmaceuticals
TEVA
$40.6B
| $48.7M | 1.5% |
5,000,000
-500,000
| -9% | -$4.68M |
|
|
27
CALL
Sanofi
SNY
$103B
| $48.2M | 1.48% |
+1,000,000
| New | +$50.8M |
|
28
OraSure Technologies
OSUR
$275M
| $48.1M | 1.48% |
4,250,000
+675,000
| +19% | +$7.41M |
|
|
29
Sarepta Therapeutics
SRPT
$1.77B
| $46.2M | 1.42% |
+500,000
| New | +$38.5M |
|
30
Collegium Pharmaceutical
COLL
$944M
| $39.5M | 1.22% |
2,000,000
| – | – |
|
31
PTC Therapeutics
PTCT
$5.91B
| $27.9M | 0.86% |
+750,000
| New | +$30.8M |
|
32
iRhythm Holdings
IRTC
$4.21B
| $27.8M | 0.86% |
+475,000
| New | +$25.2M |
|
33
Puma Biotechnology
PBYI
$413M
| $24M | 0.74% |
3,425,000
+700,000
| +26% | +$5.24M |
|
34
Zymeworks
ZYME
$1.7B
| $21.8M | 0.67% |
+750,000
| New | +$24.9M |
|
35
Biogen
BIIB
$30.5B
| $21.2M | 0.65% |
+75,000
| New | +$24.6M |
|
|
RDUS
36
DELISTED
Radius Health, Inc.
RDUS
| $18.6M | 0.57% |
1,500,000
| – | – |
|
37
Theravance Biopharma
TBPH
$877M
| $18.5M | 0.57% |
+2,500,000
| New | +$28M |
|
|
TECX
38
Tectonic Therapeutic
TECX
$570M
| $17.5M | 0.54% |
261,111
| – | – |
|
39
InnovAge Holding
INNV
$1.49B
| $6.61M | 0.2% |
1,000,000
-253,000
| -20% | -$3.92M |
|
|
40
Cardinal Health
CAH
$55.7B
| – | – |
-1,250,000
| Closed | -$71.4M |
|
|
HOLX
41
DELISTED
Hologic
HOLX
| – | – |
-665,000
| Closed | -$44.4M |
|
42
CALL
Pfizer
PFE
$149B
| – | – |
-2,000,000
| Closed | -$78.3M |
|
|
43
SkinHealth Systems
SKIN
$99.5M
| – | – |
-4,000,000
| Closed | -$67.2M |
|
|
TBIO
44
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| – | – |
-1,400,000
| Closed | -$38.6M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Camber Capital Management held 44 positions worth $3.25B, up 9.4% from $2.97B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Camber Capital Management deployed $431M of net new capital in Q3 2021, opening 10 new positions and adding to 12 existing holdings. Its largest new stake was Zimmer Biomet: 746,843 shares worth $106M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Alkermes, an estimated $44.5M trimmed.
- Camber Capital Management's largest Q3 2021 buy was Zimmer Biomet: 746,843 shares worth $106M.
- Camber Capital Management added most to Universal Health Services in Q3 2021, an estimated $102M increase.
- Camber Capital Management's biggest Q3 2021 reduction was Alkermes, cutting an estimated $44.5M.
- Camber Capital Management fully exited Cardinal Health in Q3 2021, selling an estimated $71.4M.
- Camber Capital Management's ten largest holdings make up 47% of its $3.25B portfolio in Q3 2021.
- Camber Capital Management opened 10 new positions and closed 5 in Q3 2021.
- Camber Capital Management's portfolio value rose 9.4% quarter-over-quarter to $3.25B.
Based on Camber Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.